Successful Hemostasis with Extended Half-life Recombinant Factor VIII in Circumcision

Kaynakça (11)

1. Ingerslev J, Hvid I. Surgery in hemophilia. The general view: patient selection, timing, and preoperative assessment. Semin Hematol 2006;43:23-26
2. Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, Llinas A, Ludlam CA, Mahlangu JN, Mulder K, Poon MC, Street A; Treatment Guidelines Working Group on Behalf of the World Federation of Hemophilia. Guidelines for the management of hemophilia. Haemophilia 2013;19:e1-e47
3. Konkle BA, Stasyshyn O, Chowdary P, Bevan DH, Mant T, Shima M, Engl W, Dyck-Jones J, Fuerlinger M, Patrone L, Ewenstein B, Abbuehl B. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood 2015;126:1078-1085
4. Rizvi SAH, Naqvi SAA, Hussain M, Hasan AS. Religious circumcision: a Muslim view. BJU Int 1999;83(Suppl.1):13-16
5. Kavakli K, Kurugol Z, Goksen D, Nisli G. Should hemophiliac patients be circumcised? Pediatr Hematol Oncol 2000;17:149-153
6. Zulfikar B, Karaman MI, Ovali F. Circumcision in Hemophilia. An Overview. Treatment of Hemophilia. Montreal, World Federation of Hemophilia, 2003
7. Karaman MI, Zulfikar B, Özturk MI, Koca O, Akyüz M, Bezgal F. Circumcision in bleeding disorders: improvement of our cost effective method with diathermic knife. Urol J 2014;11:1406-1410
8. Avanoglu A, Celik A, Ulman I, Özcan C, Kavaklı K, Nişli G, Gökdemir A. Safer circumcision in patients with hemophilia: the use of fibrin glue for local hemostasis. BJU Int 1999;83:91-94
9. Hampton K, Chowdary P, Dunkley S, Ehrenforth S, Jacobsen L, Neff A, Santagostino E, Sathar J, Takedani H, Takemoto CM, Négrier C. First report on the safety and efficacy of an extended half‐life glyco PEG ylated recombinant FVIII for major surgery in severe haemophilia A. Haemophilia 2017;23:689-696
10. Mahlangu JN, Ragni M, Gupta N, Rangarajan S, Klamroth R, Oldenburg J, Nogami K, Young G, Cristiano LM, Dong Y, Allen G, Pierce GF, Robinson B. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thromb Haemost 2016;116:1-8
11. Brand B, Gruppo R, Wynn TT, Griskevicius L, Lopez Fernandez MF, Chapman M, Dvorak T, Pavlova BG, Abbuehl BE. Efficacy and safety of pegylated full‐ length recombinant factor VIII with extended half‐life for perioperative haemostasis in haemophilia A patients. Haemophilia 2016;22:e251-e258.